{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:57:00Z","timestamp":1794448620624,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Science Foundation of China","award":["No. 81960664"],"award-info":[{"award-number":["No. 81960664"]}]},{"name":"the Applied Basic Research Program Yunnan Province of China","award":["No. 202101AY070001-300"],"award-info":[{"award-number":["No. 202101AY070001-300"]}]},{"name":"the Science and Technology Planning Project of 920th Hospital of Joint Logistics Support Force of People\u2019s Liberation Army","award":["No. 2020YGB11"],"award-info":[{"award-number":["No. 2020YGB11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10067-022-06356-z","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:02:21Z","timestamp":1661731341000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Ya-Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-3130","authenticated-orcid":false,"given":"Gong-Hao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"issue":"3S","key":"6356_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50(3S):S11\u2013S16. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.008","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"6356_CR2","first-page":"71","volume":"78","author":"RYM The","year":"2019","unstructured":"The RYM, Daniel K (2019) Inouye College of Pharmacy Scripts: perspectives on the epidemiology of gout and hyperuricemia. Hawaii J Med Public Health 78(2):71\u201376","journal-title":"Hawaii J Med Public Health"},{"issue":"7","key":"6356_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16(7):380\u2013390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1","journal-title":"Nat Rev Rheumatol"},{"issue":"13","key":"6356_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/VHRM.S115080","volume":"8","author":"M Bove","year":"2017","unstructured":"Bove M, Cicero AF, Veronesi M, Borghi C (2017) An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag 8(13):23\u201328. https:\/\/doi.org\/10.2147\/VHRM.S115080","journal-title":"Vasc Health Risk Manag"},{"issue":"12","key":"6356_CR5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/14656566.2017.1351945","volume":"18","author":"T Pascart","year":"2017","unstructured":"Pascart T, Richette P (2017) Current and future therapies for gout. Expert Opin Pharmacother 18(12):1201\u20131211. https:\/\/doi.org\/10.1080\/14656566.2017.1351945","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"6356_CR6","doi-asserted-by":"publisher","first-page":"641062","DOI":"10.3389\/fcvm.2021.641062","volume":"23","author":"H Ying","year":"2021","unstructured":"Ying H, Yuan H, Tang X, Guo W, Jiang R, Jiang C (2021) Impact of serum uric acid lowering and contemporary uric acid-lowering therapies on cardiovascular outcomes: a systematic review and meta-analysis. Front Cardiovasc Med 23(8):641062. https:\/\/doi.org\/10.3389\/fcvm.2021.641062","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"6356_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-021-05930-1","volume":"41","author":"TL Jansen","year":"2022","unstructured":"Jansen TL, Tanja G, Matthijs J (2022) A historical journey of searching for uricosuric drugs. Clin Rheumatol 41(1):297\u2013305. https:\/\/doi.org\/10.1007\/s10067-021-05930-1","journal-title":"Clin Rheumatol"},{"issue":"907","key":"6356_CR8","doi-asserted-by":"publisher","first-page":"174291","DOI":"10.1016\/j.ejphar.2021.174291","volume":"15","author":"D Song","year":"2021","unstructured":"Song D, Zhao X, Wang F, Wang G (2021) A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications. Eur J Pharmacol 15(907):174291. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174291","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"6356_CR9","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/DDDT.S97959","volume":"24","author":"G Jones","year":"2017","unstructured":"Jones G, Panova E, Day R (2017) Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther 24(11):3077\u20133081. https:\/\/doi.org\/10.2147\/DDDT.S97959","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"6356_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clinthera.2016.12.011","volume":"39","author":"RT Keenan","year":"2017","unstructured":"Keenan RT (2017) Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review. Clin Ther 39(2):430\u2013441. https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.011","journal-title":"Clin Ther"},{"issue":"8","key":"6356_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1517\/13543784.2015.1051617","volume":"24","author":"H Shahid","year":"2015","unstructured":"Shahid H, Singh JA (2015) Investigational drugs for hyperuricemia. Expert Opin Investig Drugs 24(8):1013\u20131030. https:\/\/doi.org\/10.1517\/13543784.2015.1051617","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"6356_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.semarthrit.2018.06.004","volume":"48","author":"F Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz F, Dalbeth N (2019) Combination urate-lowering therapy in the treatment of gout: what is the evidence? Semin Arthritis Rheum 48(4):658\u2013668. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.06.004","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"6356_CR13","first-page":"983","volume":"20","author":"C Borghi","year":"2016","unstructured":"Borghi C, Perez-Ruiz F (2016) Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 20(5):983\u2013992","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"6356_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/phar.2183","volume":"38","author":"JY Wu","year":"2018","unstructured":"Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW (2018) Efficacy and safety of lesinurad in patients with hyperuricemia associated with gout: a systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy 38(11):1106\u20131119. https:\/\/doi.org\/10.1002\/phar.2183","journal-title":"Pharmacotherapy"},{"issue":"1","key":"6356_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","volume":"40","author":"X Liu","year":"2018","unstructured":"Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L (2018) Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail 40(1):289\u2013297. https:\/\/doi.org\/10.1080\/0886022X.2018.1456463","journal-title":"Ren Fail"},{"issue":"7","key":"6356_CR16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","volume":"56","author":"T Zhang","year":"2017","unstructured":"Zhang T, Pope JE (2017) Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford) 56(7):1144\u20131153. https:\/\/doi.org\/10.1093\/rheumatology\/kex065","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"6356_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","volume":"19","author":"T Kanji","year":"2015","unstructured":"Kanji T, Gandhi M, Clase CM, Yang R (2015) Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 19(16):58. https:\/\/doi.org\/10.1186\/s12882-015-0047-z","journal-title":"BMC Nephrol"},{"issue":"8","key":"6356_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/10641963.2021.1950752","volume":"43","author":"T Takahashi","year":"2021","unstructured":"Takahashi T, Beppu T, Hidaka Y, Hosoya T (2021) Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials. Clin Exp Hypertens 43(8):730\u2013741. https:\/\/doi.org\/10.1080\/10641963.2021.1950752","journal-title":"Clin Exp Hypertens"},{"issue":"4","key":"6356_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14656566.2021.2020249","volume":"23","author":"KEG Blake","year":"2022","unstructured":"Blake KEG, Saag JL, Saag KG (2022) What\u2019s new on the front-line of gout pharmacotherapy? Expert Opin Pharmacother 23(4):453\u2013464. https:\/\/doi.org\/10.1080\/14656566.2021.2020249","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"6356_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"issue":"1","key":"6356_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR (2009) Efficacy and tolerability of urate-lowering drugs in gout: a randomized controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68(1):51\u201356. https:\/\/doi.org\/10.1136\/ard.2007.083071","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"6356_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T (2020) Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol 24(Suppl 1):53\u201361. https:\/\/doi.org\/10.1007\/s10157-019-01818-2","journal-title":"Clin Exp Nephrol"},{"issue":"Suppl 1","key":"6356_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-019-01802-w","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T (2020) Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol 24(Suppl 1):44\u201352. https:\/\/doi.org\/10.1007\/s10157-019-01802-w","journal-title":"Clin Exp Nephrol"},{"issue":"Suppl 1","key":"6356_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10157-020-01849-0","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T (2020) Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol 24(Suppl 1):62\u201370. https:\/\/doi.org\/10.1007\/s10157-020-01849-0","journal-title":"Clin Exp Nephrol"},{"issue":"Suppl 1","key":"6356_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10157-019-01831-5","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T (2020) Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol 24(Suppl 1):80\u201391. https:\/\/doi.org\/10.1007\/s10157-019-01831-5","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"6356_CR26","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K (2017) Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 1 56(12):2170\u20132178. https:\/\/doi.org\/10.1093\/rheumatology\/kex350","journal-title":"Rheumatology (Oxford) 1"},{"key":"6356_CR27","unstructured":"NCT01399008 (2012) Safety\/efficacy study to evaluate of MBX-102 in combination with allopurinol in gout patients. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01399008"},{"issue":"6","key":"6356_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","volume":"29","author":"D Fitz-Patrick","year":"2019","unstructured":"Fitz-Patrick D, Roberson K, Niwa K, Fujimura T, Mori K, Hall J, Yan X, Shen Z, Liu S, Ito Y, Baumgartner S (2019) Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: findings from two phase II trials. Mod Rheumatol 29(6):1042\u20131052. https:\/\/doi.org\/10.1080\/14397595.2018.1538003","journal-title":"Mod Rheumatol"},{"issue":"9","key":"6356_CR29","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","volume":"57","author":"M Shiramoto","year":"2018","unstructured":"Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, Ito Y, Hall J (2018) Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford) 57(9):1602\u20131610. https:\/\/doi.org\/10.1093\/rheumatology\/key100","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"6356_CR30","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"J Poiley","year":"2016","unstructured":"Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, Boudes PF, Arhalofenate Flare Study Investigators (2016) A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol 68(8):2027\u20132034. https:\/\/doi.org\/10.1002\/art.39684","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"6356_CR31","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Y Lin","year":"2021","unstructured":"Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, Jiang Z, Li D, Wang Z, Long W, Li Z, Jiang G, Li X, Bi L, Jiang L, Wu J, Guo L, Cai X, Lu X, Chen Q, Chen H, Peng A, Zuo X, Ning R, Zhang Z, Tai Y, Zhang T, Bao C (2021) Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford) 3 60(11):5089\u20135097. https:\/\/doi.org\/10.1093\/rheumatology\/keab198","journal-title":"Rheumatology (Oxford) 3"},{"issue":"1","key":"6356_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","volume":"3","author":"K Ogino","year":"2010","unstructured":"Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W (2010) Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 3(1):73\u201381. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.868604","journal-title":"Circ Heart Fail"},{"issue":"11","key":"6356_CR33","doi-asserted-by":"publisher","first-page":"CD010457","DOI":"10.1002\/14651858.CD010457.pub2","volume":"14","author":"AS Kydd","year":"2014","unstructured":"Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C (2014) Uricosuric medications for chronic gout. Cochrane Database Syst Rev 14(11):CD010457. https:\/\/doi.org\/10.1002\/14651858.CD010457.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6356_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liot\u00e9 F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6356_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T (2020) 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 72(6):744\u2013760. https:\/\/doi.org\/10.1002\/acr.24180","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"6356_CR36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3899\/jrheum.121301","volume":"40","author":"K Pui","year":"2013","unstructured":"Pui K, Gow PJ, Dalbeth N (2013) Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 40(6):872\u2013876. https:\/\/doi.org\/10.3899\/jrheum.121301","journal-title":"J Rheumatol"},{"issue":"9","key":"6356_CR37","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"MK Reinders","year":"2007","unstructured":"Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL (2007) Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26(9):1459\u20131465. https:\/\/doi.org\/10.1007\/s10067-006-0528-3","journal-title":"Clin Rheumatol"},{"issue":"5","key":"6356_CR38","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3899\/jrheum.101160","volume":"38","author":"SL Stocker","year":"2011","unstructured":"Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO (2011) Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 38(5):904\u2013910. https:\/\/doi.org\/10.3899\/jrheum.101160","journal-title":"J Rheumatol"},{"issue":"6","key":"6356_CR39","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, RDEA594-203 Study Group (2016) Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis 75(6):1074\u20131080. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207919","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6356_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","volume":"18","author":"L Strilchuk","year":"2019","unstructured":"Strilchuk L, Fogacci F, Cicero AF (2019) Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf 18(4):261\u2013271. https:\/\/doi.org\/10.1080\/14740338.2019.1594771","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"6356_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jcpt.13156","volume":"45","author":"SS Sun","year":"2020","unstructured":"Sun SS, Zhang DH, Shi Y, Lin CJ, Lin JY (2020) Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: a comprehensive network meta-analysis of randomized controlled trials. J Clin Pharm Ther 45(4):729\u2013742. https:\/\/doi.org\/10.1111\/jcpt.13156","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"6356_CR42","doi-asserted-by":"publisher","first-page":"33082","DOI":"10.1038\/srep33082","volume":"8","author":"S Li","year":"2016","unstructured":"Li S, Yang H, Guo Y, Wei F, Yang X, Li D, Li M, Xu W, Li W, Sun L, Gao Y, Wang Y (2016) Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep 8(6):33082. https:\/\/doi.org\/10.1038\/srep33082","journal-title":"Sci Rep"},{"key":"6356_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/IJNRD.S6048","volume":"3","author":"N Dubchak","year":"2010","unstructured":"Dubchak N, Falasca GF (2010) New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis 3:145\u2013166. https:\/\/doi.org\/10.2147\/IJNRD.S6048","journal-title":"Int J Nephrol Renovasc Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06356-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:09:42Z","timestamp":1672963782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06356-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6356"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06356-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}